Team Veye June 04, 2026

Pro Medicus Announces $16m Contract Renewal, Signifying its Track Record of Client Retention

Get your Free Report on Top 5 ASX stocks for 2025

Pro Medicus Limited (ASX: PME) has announced a 5 year, $16 million contract renewal with The Ohio State University Wexner Medical Center. This will extend a key U.S. client relationship and add new workflow and cardiology imaging modules. The deal was negotiated with higher minimums and a larger fee per transaction, reinforcing the company’s transaction-based growth model.

The renewal which is signed through wholly owned U.S. subsidiary Visage Imaging, Inc. expands the existing deployment to include Visage 7 Workflow and Visage 7 Cardiology Imaging at the Columbus based academic medical center. OSUWMC is a major healthcare network with about 22,000 staff, 2,000 physicians and more than 1,400 inpatient beds across six hospitals.

Pro Medicus noted the contract reflects customer demand for its native capabilities as hospitals look to retire legacy systems and scale their enterprise imaging platforms. Management also said that the agreement lifts total renewals for the financial year to $141 million which underscores strong client retention and recurring revenue visibility.

The deal adds further momentum to PME’s broader Visage 7 platform rollout with the company positioning its software as a scalable solution across cloud environments and advanced imaging use cases.

For investors, the renewal supports the case for durable cash flows and continued expansion in the U.S. healthcare imaging market.

(Source: Company Announcement)

Disclaimer

Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.

Name

Email address

Phone

By providing your details, you agree to Veye’s Terms & Conditions, Privacy Policy, and Financial Services Guide and to receive marketing offers by email, text message or phone call from us or our agents until you opt out. Before you access our services, please read the Financial Service Guide available here.